Overview

Pilot Study to Evaluate the Impact of Denosumab on Disseminated Tumor Cells (DTC) in Patients With Early Stage Breast Cancer

Status:
Terminated

Trial end date:
2016-06-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see whether taking denosumab for 12 months in women with a significant number of disseminated tumor cells in the bone marrow can reduce the number of these cells below a significant level.

Phase:

Phase 2

Details

Lead Sponsor:

Hope Rugo, MD

Collaborators:

Amgen
University of California, San Francisco

Treatments:

Denosumab